Abstract:Background and Objective: Radiotherapy (RT) is one of the fundamental anti-cancer regimens by means of inducing in situ tumor vaccination and driving a systemic anti-tumor immune response. It can affect the tumor microenvironment (TME) components consisting of blood vessels, immunocytes, fibroblasts, and extracellular matrix (ECM), and might subsequently suppress anti-tumor immunity through expression of molecules such as programmed death ligand-1 (PD-L1). Immune checkpoint inhibitors (ICIs), especially anti-programmed cell death 1 (PD-1)/PD-L1 therapies, have been regarded as effective in the reinvigoration of the immune system and another major cancer treatment. Experimentally, combination of RT and ICIs therapy shows a greater synergistic effect than either therapy alone.Methods: We performed a narrative review of the literature in the PubMed database. The research string comprised various combinations of "radiotherapy", "programmed death-ligand 1", "microenvironment", "exosome", "myeloid cell", "tumor cell", "tumor immunity". The database was searched independently by two authors. A third reviewer mediated any discordance of the results of the two screeners.Key Content and Findings: RT upregulates PD-L1 expression in tumor cells, tumor-derived exosomes (TEXs), myeloid-derived suppressor cells (MDSCs), and macrophages. The signaling pathways correlated to PD-L1 expression in tumor cells include the DNA damage signaling pathway, epidermal growth factor receptor (EGFR) pathway, interferon gamma (IFN-γ) pathway, cGAS-STING pathway, and JAK/STATs pathway.Conclusions: PD-L1 upregulation post-RT is found not only in tumor cells but also in the TME and is one of the mechanisms of tumor evasion. Therefore, further studies are necessary to fully comprehend this biological process. Meanwhile, combination of therapies has been shown to be effective, and novel approaches are to be developed as adjuvant to RT and ICIs therapy.

Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance

Targeting Tumor Physical Microenvironment for Improved Radiotherapy

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy

Advances in targeting tumor microenvironment for immunotherapy

Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy

Radiation-induced Tumor Immune Microenvironments and Potential Targets for Combination Therapy

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Role of tumor microenvironment in cancer progression and therapeutic strategy

Radiotherapy-activated tumor immune microenvironment: Realizing radiotherapy-immunity combination therapy strategies

Immune targets in the tumor microenvironment treated by radiotherapy

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment

The Influence of Microenvironment on Tumor Immunotherapy

Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review

Biomaterials tools to modulate the tumour microenvironment in immunotherapy

3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment

Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance